Please Wait.....
Report
Global Allogeneic T Cell Therapies Market Report and Forecast 2024-2032
Market Report I 2023-09-05 I 160 Pages I EMR Inc.
Global Allogeneic T Cell Therapies Market Report and Forecast 2024-2032
Global Allogeneic T-Cell Therapies Market Outlook
The growth of the global allogeneic T cell therapies market size is being driven by the increasing interest of pharmaceutical companies across the globe. The market size is anticipated to grow at a CAGR of 9.8% during the forecast period of 2024-2032.
Allogeneic T Cell Therapies: Introduction
Allogeneic T cell therapies are a type of immunotherapy that harnesses the power of T cells from healthy donors to treat various diseases, particularly cancer. T cells, a type of white blood cells, play a central role in the immune system's response to foreign substances, such as cancer cells or pathogens. Allogeneic T cell therapies involve isolating T cells from healthy donors, modifying them to enhance their anti-cancer activity, and then infusing them into patients to target and destroy cancer cells.
Allogeneic T cell therapies have shown promising results in the treatment of various haematological malignancies, including leukaemia, lymphoma, and multiple myeloma. They are also being investigated for solid tumours and other diseases, such as viral infections and autoimmune disorders. Ongoing research aims to optimize their efficacy, safety, and applicability to a broader range of diseases.
Key Trends in the Global Allogeneic T Cell TherapiesMarket
Key trends in the allogeneic T cell therapies market:
- Advancements in Genetic Engineering: The field of genetic engineering is rapidly evolving, and there are ongoing efforts to enhance the anti-cancer properties of allogeneic T-cell therapies. Researchers are exploring novel gene-editing techniques, such as CRISPR/Cas9, to precisely modify T cells and improve their efficacy and safety profiles.
- Expansion into Solid Tumours: While allogeneic T cell therapies have shown remarkable success in hematological malignancies, there is a growing focus on expanding their applications to solid tumors. Researchers are working on identifying suitable target antigens and developing strategies to overcome the challenges associated with the tumor microenvironment.
- Combination Therapies: Combining allogeneic T-cell therapies with other treatment modalities, such as immune checkpoint inhibitors, targeted therapies, or radiation, is gaining attention. Combination therapies have the potential to enhance the effectiveness of allogeneic T-cell therapies by promoting a synergistic anti-cancer immune response. Clinical trials evaluating the safety and efficacy of combination approaches are ongoing, and positive results could lead to the development of more effective treatment regimens.
- Scalable Manufacturing Processes: With the increasing demand for allogeneic T-cell therapies, there is a need for scalable and cost-effective manufacturing processes. Researchers and companies are focusing on developing efficient manufacturing strategies that can produce large quantities of consistent and high-quality allogeneic T-cell products.
- Expansion of Clinical Trials: The number of clinical trials investigating allogeneic T-cell therapies is rapidly expanding. These trials aim to evaluate the safety, efficacy, and long-term outcomes of these therapies in different cancer types and patient populations. Additionally, clinical trials are exploring the use of allogeneic T-cell therapies in combination with other treatments or as a follow-up therapy after stem cell transplantation.
Global Allogeneic T Cell TherapiesMarket Segmentations
The market can be categorized into product type, therapeutics indications, end user, and region.
Market Breakup by Product Type
- Chimeric Antigen Receptor (CAR) T Cell Therapies
- T Cell Receptor (TCR) Therapies
- Others
Market Breakup by Therapeutics Indications
- Cancer
- Autoimmune Diseases
- Infectious Diseases
- Others
Market Breakup by End User
- Hospitals
- Speciality Clinics
- Research Institutes
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Allogeneic T Cell Therapies Market Overview
The market for allogeneic T-cell therapies is experiencing substantial growth. The increasing prevalence of cancer and the demand for more effective treatment options are driving the market expansion. The market is expected to witness significant investments in research and development, manufacturing infrastructure, and commercialization activities. The allogeneic T cell therapies market is becoming increasingly competitive, with several biotechnology and pharmaceutical companies actively participating in research and development. Companies are striving to establish a competitive edge through innovative technologies, partnerships, and therapeutic advancements.
As allogeneic T cell therapies approach commercialization, access and affordability are significant considerations. The high costs of these therapies raise concerns about equitable access for patients. Payers and healthcare systems are grappling with reimbursement models that ensure patient access to these novel and potentially life-saving treatments. In summary, the allogeneic T cell therapies market is witnessing rapid growth and remarkable progress in the treatment of various cancers. Ongoing research, technological advancements, and regulatory developments will play pivotal roles.
Key Players in the Global Allogeneic T Cell Therapies Market
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the allogeneic T cell therapies market are as follows:
- Athersys Inc.
- Mesoblast Ltd.
- Biorestorative Therapies Inc.
- Pluristem Inc.
- Brainstorm Cell Limited.
- ViaCyte Inc.
- Gamida Cell
- HOPE BIOSCIENCES
- Cellular Biomedicine Group
- Smith+Nephew
- MEDIPOST
- ANTEROGEN.CO, LTD.
- NuVasive Inc.
- RTI Surgical
- AlloSource
- JCR Pharmaceuticals Co. Ltd.
- Takeda Pharmaceutical Company Limited
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.
1Preface
1.1Objectives of the Study
1.2Key Assumptions
1.3Report Coverage - Key Segmentation and Scope
1.4Research Methodology
2Executive Summary
3Global Allogeneic T Cell Therapies Market Overview
3.1Global Allogeneic T Cell Therapies Market Historical Value (2017-2023)
3.2Global Allogeneic T Cell Therapies Market Forecast Value (2024-2032)
4Global Allogeneic T Cell Therapies Market Landscape
4.1Global Allogeneic T Cell Therapies Developers Landscape
4.1.1Analysis by Year of Establishment
4.1.2Analysis by Company Size
4.1.3Analysis by Region
4.2Global Allogeneic T Cell Therapies Product Landscape
4.2.1Analysis by Product Type
4.2.2Analysis by Indications
4.2.3Analysis by End User
5Global Allogeneic T Cell Therapies Market Dynamics
5.1Market Drivers and Constraints
5.2SWOT Analysis
5.3Porter's Five Forces Model
5.4Key Demand Indicators
5.5Key Price Indicators
5.6Industry Events, Initiatives, and Trends
5.7Value Chain Analysis
6Global Allogeneic T Cell Therapies Market Segmentation
6.1Global Allogeneic T Cell Therapies Market by Product Type
6.1.1Market Overview
6.1.2Chimeric Antigen Receptor (CAR) T Cell Therapies
6.1.3T Cell Receptor (TCR) Therapies
6.1.4Others
6.2Global Allogeneic T Cell Therapies Market by Therapeutics Indications
6.2.1Market Overview
6.2.2Cancer
6.2.3Autoimmune Diseases
6.2.4Infectious Diseases
6.2.5Others
6.3Global Allogeneic T Cell Therapies Market by End User
6.3.1Market Overview
6.3.2Hospitals
6.3.3Specialty Clinics
6.3.4Research Institutes
6.3.5Others
6.4Global Allogeneic T Cell Therapies Market by Region
6.4.1Market Overview
6.4.2North America
6.4.3Europe
6.4.4Asia Pacific
6.4.5Latin America
6.4.6Middle East and Africa
7North America Allogeneic T Cell Therapies Market
7.1Market Share by Country
7.2United States of America
7.3Canada
8Europe Allogeneic T Cell Therapies Market
8.1Market Share by Country
8.2United Kingdom
8.3Germany
8.4France
8.5Italy
8.6Others
9Asia Pacific Allogeneic T Cell Therapies Market
9.1Market Share by Country
9.2China
9.3Japan
9.4India
9.5ASEAN
9.6Australia
9.7Others
10Latin America Allogeneic T Cell Therapies Market
10.1Market Share by Country
10.2Brazil
10.3Argentina
10.4Mexico
10.5Others
11Middle East and Africa Allogeneic T Cell Therapies Market
11.1Market Share by Country
11.2Saudi Arabia
11.3United Arab Emirates
11.4Nigeria
11.5South Africa
11.6Others
12Patent Analysis
12.1Analysis by Type of Patent
12.2Analysis by Publication year
12.3Analysis by Issuing Authority
12.4Analysis by Patent Age
12.5Analysis by CPC Analysis
12.6Analysis by Patent Valuation
12.7Analysis by Key Players
13Grants Analysis
13.1Analysis by year
13.2Analysis by Amount Awarded
13.3Analysis by Issuing Authority
13.4Analysis by Grant Application
13.5Analysis by Funding Institute
13.6Analysis by NIH Departments
13.7Analysis by Recipient Organization
14Funding Analysis
14.1Analysis by Funding Instances
14.2Analysis by Type of Funding
14.3Analysis by Funding Amount
14.4Analysis by Leading Players
14.5Analysis by Leading Investors
14.6Analysis by Geography
15Partnership and Collaborations Analysis
15.1Analysis by Partnership Instances
15.2Analysis by Type of Partnership
15.3Analysis by Leading Players
15.4Analysis by Geography
16Regulatory Framework
16.1Regulatory Overview
16.1.1US FDA
16.1.2EU EMA
16.1.3INDIA CDSCO
16.1.4JAPAN PMDA
16.1.5Others
17Supplier Landscape
17.1Athersys Inc.
17.1.1Financial Analysis
17.1.2Product Portfolio
17.1.3Demographic Reach and Achievements
17.1.4Mergers and Acquisition
17.1.5Certifications
17.2Mesoblast Ltd.
17.2.1Financial Analysis
17.2.2Product Portfolio
17.2.3Demographic Reach and Achievements
17.2.4Mergers and Acquisition
17.2.5Certifications
17.3Biorestorative Therapies Inc.
17.3.1Financial Analysis
17.3.2Product Portfolio
17.3.3Demographic Reach and Achievements
17.3.4Mergers and Acquisition
17.3.5Certifications
17.4Pluristem Inc.
17.4.1Financial Analysis
17.4.2Product Portfolio
17.4.3Demographic Reach and Achievements
17.4.4Mergers and Acquisition
17.4.5Certifications
17.5Brainstorm Cell Limited.
17.5.1Financial Analysis
17.5.2Product Portfolio
17.5.3Demographic Reach and Achievements
17.5.4Mergers and Acquisition
17.5.5Certifications
17.6ViaCyte Inc.
17.6.1Financial Analysis
17.6.2Product Portfolio
17.6.3Demographic Reach and Achievements
17.6.4Mergers and Acquisition
17.6.5Certifications
17.7Gamida Cell
17.7.1Financial Analysis
17.7.2Product Portfolio
17.7.3Demographic Reach and Achievements
17.7.4Mergers and Acquisition
17.7.5Certifications
17.8HOPE BIOSCIENCES
17.8.1Financial Analysis
17.8.2Product Portfolio
17.8.3Demographic Reach and Achievements
17.8.4Mergers and Acquisition
17.8.5Certifications
17.9Cellular Biomedicine Group
17.9.1Financial Analysis
17.9.2Product Portfolio
17.9.3Demographic Reach and Achievements
17.9.4Mergers and Acquisition
17.9.5Certifications
17.10Smith+Nephew
17.10.1Financial Analysis
17.10.2Product Portfolio
17.10.3Demographic Reach and Achievements
17.10.4Mergers and Acquisition
17.10.5Certifications
17.11MEDIPOST
17.11.1Financial Analysis
17.11.2Product Portfolio
17.11.3Demographic Reach and Achievements
17.11.4Mergers and Acquisition
17.11.5Certifications
17.12ANTEROGEN.CO, LTD.
17.12.1Financial Analysis
17.12.2Product Portfolio
17.12.3Demographic Reach and Achievements
17.12.4Mergers and Acquisition
17.12.5Certifications
17.13NuVasive Inc.
17.13.1Financial Analysis
17.13.2Product Portfolio
17.13.3Demographic Reach and Achievements
17.13.4Mergers and Acquisition
17.13.5Certifications
17.14RTI Surgical
17.14.1Financial Analysis
17.14.2Product Portfolio
17.14.3Demographic Reach and Achievements
17.14.4Mergers and Acquisition
17.14.5Certifications
17.15AlloSource
17.15.1Financial Analysis
17.15.2Product Portfolio
17.15.3Demographic Reach and Achievements
17.15.4Mergers and Acquisition
17.15.5Certifications
17.16JCR Pharmaceuticals Co. Ltd.
17.16.1Financial Analysis
17.16.2Product Portfolio
17.16.3Demographic Reach and Achievements
17.16.4Mergers and Acquisition
17.16.5Certifications
17.17Takeda Pharmaceutical Company Limited
17.17.1Financial Analysis
17.17.2Product Portfolio
17.17.3Demographic Reach and Achievements
17.17.4Mergers and Acquisition
17.17.5Certifications
18Global Allogeneic T Cell Therapies Market - Distribution Model (Additional Insight)
18.1Overview
18.2Potential Distributors
18.3Key Parameters for Distribution Partner Assessment
19Key Opinion Leaders (KOL) Insights (Additional Insight)
20Company Competitiveness Analysis (Additional Insight)
20.1Very Small Companies
20.2Small Companies
20.3Mid-Sized Companies
20.4Large Companies
20.5Very Large Companies
21Payment Methods (Additional Insight)
21.1Government Funded
21.2Private Insurance
21.3Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security